Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | IL4 | P05112 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12202948 | 0.81 | ADORA3 (0.41) | ADORA3ADORA2AGCGRRAB9ANPC1 | |
| SCHEMBL12228276 | 0.81 | KDM4E (0.45) | ADORA3ADORA2ARAB9AMEN1KMT2A | |
| SCHEMBL3840856 | 0.80 | AURKA (0.56) | ADORA3ADORA2ARAB9AADORA1KDM4E | |
| SCHEMBL8083250 | 0.78 | TDP1 (0.49) | ADORA3ADORA2ARAB9AADORA1KDM4E | |
| SCHEMBL6586854 | 0.77 | NPC1 (0.44) | ADORA3ADORA2AIL4RAB9AMEN1 | |
| SCHEMBL3451092 | 0.77 | ALOX5 (0.44) | ADORA3ADORA2AIL4RAB9AMEN1 | |
| SCHEMBL12228687 | 0.76 | ADORA2A (0.40) | ADORA3ADORA2ARAB9AKMT2AADORA1 | |
| SCHEMBL7951847 | 0.76 | KDM4E (0.38) | ADORA3ADORA2AGCGRRAB9AADORA1 | |
| SCHEMBL12228275 | 0.75 | MAPT (0.39) | ADORA3ADORA2ARAB9AMEN1NPC1 | |
| SCHEMBL28302182 | 0.75 | LMNA (0.62) | ADORA3ADORA2ARAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751142-A | Impurity of rosuvastatin calcium intermediate and preparation process thereof | 湖南方盛绿色合成制药有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-101084197-B | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD | 2012-06-13 | — | — | CN | claimed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| CN-101218210-B | Processes for the manufacture of rosuvastatin and intermediates | ASTRAZENECA UK LTD | 2011-08-03 | — | — | CN | claimed |
| US-20100228028-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| CN-101218210-A | Processes for the manufacture of rosuvastatin and intermediates | ASTRAZENECA UK LTD (GB) | 2008-07-09 | — | — | CN | claimed |
| EP-1904456-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | AstraZeneca UK Limited (GB) | 2008-04-02 | — | — | EP | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| CN-101084197-A | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD (GB) | 2007-12-05 | — | — | CN | claimed |
| WO-2007007119-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2007-01-18 | — | — | WO | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| CN-116751142-A | Impurity of rosuvastatin calcium intermediate and preparation process thereof | 湖南方盛绿色合成制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| CN-101084197-A | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD (GB) | 2007-12-05 | — | — | CN | disclosed |
| WO-2007007119-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007119-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228028-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | HMGCR, PCSK9, CYP4A11 | ADORA3 2345/4885ADORA2A 3052/4885IL4 2681/4885 |
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | ADORA3 4668/4885ADORA2A 4749/4885IL4 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.